SOLENO THERAPEUT. DL-001 (F:6XC) — Market Cap & Net Worth
Market Cap & Net Worth: SOLENO THERAPEUT. DL-001 (6XC)
SOLENO THERAPEUT. DL-001 (F:6XC) has a market capitalization of $2.31 Billion (€1.97 Billion) as of October 14, 2026. Listed on the F stock exchange, this Germany-based company holds position #5618 globally and #878 in its home market, demonstrating a 1.20% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying SOLENO THERAPEUT. DL-001's stock price €44.86 by its total outstanding shares 52120147 (52.12 Million).
SOLENO THERAPEUT. DL-001 Market Cap History: 2019 to 2026
SOLENO THERAPEUT. DL-001's market capitalization history from 2019 to 2026. Data shows growth from $143.80 Million to $2.73 Billion (60.30% CAGR). Check SOLENO THERAPEUT. DL-001 stock quote for real-time trading data and today's change.
SOLENO THERAPEUT. DL-001 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how SOLENO THERAPEUT. DL-001's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see 6XC cash flow conversion for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
12.62x
SOLENO THERAPEUT. DL-001's market cap is 12.62 times its annual revenue
Latest Price to Earnings (P/E) Ratio
114.98x
SOLENO THERAPEUT. DL-001's market cap is 114.98 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2025 | $2.40 Billion | $190.41 Million | $20.89 Million | 12.62x | 114.98x |
Competitor Companies of 6XC by Market Capitalization
Companies near SOLENO THERAPEUT. DL-001 in the global market cap rankings as of October 14, 2026. See 6XC equity financing ratio to understand what proportion of total assets are financed by equity.
Key companies related to SOLENO THERAPEUT. DL-001 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #197 globally with a market cap of $122.98 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #365 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #447 globally with a market cap of $63.36 Billion USD ( AU$89.55 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #510 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #197 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $122.98 Billion | $485.22 |
| #365 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $753.12 |
| #447 | CSL Ltd | AU:CSL | $63.36 Billion | AU$184.58 |
| #510 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $216.25 |
SOLENO THERAPEUT. DL-001 Historical Marketcap From 2019 to 2026
Between 2019 and today, SOLENO THERAPEUT. DL-001's market cap moved from $143.80 Million to $ 2.73 Billion, with a yearly change of 60.30%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €2.73 Billion | +13.80% |
| 2025 | €2.40 Billion | -5.96% |
| 2024 | €2.55 Billion | +101.54% |
| 2023 | €1.27 Billion | +1068.54% |
| 2022 | €108.46 Million | +358.76% |
| 2021 | €23.64 Million | -74.13% |
| 2020 | €91.40 Million | -36.44% |
| 2019 | €143.80 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 14th, 2026 the market cap of SOLENO THERAPEUT. DL-001 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.31 Billion USD |
| MoneyControl | $2.31 Billion USD |
| MarketWatch | $2.31 Billion USD |
| marketcap.company | $2.31 Billion USD |
| Reuters | $2.31 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About SOLENO THERAPEUT. DL-001
Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeut… Read more